Zanamivir® News 

Biota settles Relenza legal action
Found on 26 Jul 2008 11:01 GMT

Biota Holdings has resolved legal action it took against global pharmaceutical group GlaxoSmithKline related to its perceived lack of support for Biota's Relenza flu treatment, after the pair were ordered into ...

Glaxo Pays Biota A$20 Million to Settle Relenza Suit (Update2)
Found on 21 Jul 2008 10:17 GMT
July 21 (Bloomberg) - GlaxoSmithKline Plc , which licenses the flu drug Relenza from Biota Holdings Ltd. , paid the Australian company A$20 million ($19.5 million) to settle a lawsuit.

Relenza Labeling Revised on Neuropsychiatric Event Reports
Found on 05 Apr 2008 06:24 GMT

FDA announced today that new safety warnings about neuropsychiatric adverse events have been added to the labeling for GlaxoSmithKline's antiinfluenza drug zanamivir. via ASHP

US FDA: FDA approves Relenza (zanamivir for in inhalation) for influenza trea...
M2 PRESSWIRE-28 July 1999-US FDA: FDA approves Relenza (zanamivir for inhalation) for influenza treatment (C)1994-99 M2 COMMUNICATIONS LTD RDATE:270799 FDA has approved Relenza (zanamivir), an inhaled anti-viral drug, for adults and adolescents aged 12 years and older for the treatment of

Publication: M2 Presswire

Zanamivir for Influenza Prevention in Healthy Adults.
Amantadine and rimantadine are effective in preventing illnesses associated with type A(H3N2) and type A(H1N1) influenza viruses. A new class of antivirals, including zanamivir, which is a selective neuraminidase inhibitor, has recently been developed to decrease the duration and severity of

Publication: American Family Physician

Compared protective effect of nasal immunoprophylaxis using a new human monoc...
This study evaluated the effectiveness of five human monoclonal antibodies in comparison with human polyclonal antibodies, F(absub 2^, amantadine, and zanamivir in a mouse model of lethal influenza A virus infection. A single intranasal administration of antibodies was done for immunoprophylaxis.

Publication: Military Medicine

Drug to treat flu also protects against it.(zanamivir)(Brief Article)
For 3 decades, scientists have been experimenting with medications that stifle the influenza virus. Two drugs, amantadine and rimantadine, can impede the disease and limit symptoms. However, neither works against one of the two major strains of influenza, and both can be eluded by the evolving

Publication: Science News

Biota Announces Zanamivir Will Enter Phase III Clinical Trials in May 1997
MELBOURNE, Australia, Feb. 24 /PRNewswire/ - Biota Holdings Limited (Australian Stock Exchange: BTA) today announced that Glaxo Wellcome p1c, the Company's development partner, has informed management that Phase III clinical trials of zanamivir, or GG167, for the treatment of influenza, planned to

Publication: PR Newswire

Zanamivir Is Effective as Prophylaxis Against Influenza.
The influenza viruses are highly contagious, which partially explains the observation that 25 to 50 percent of all household contacts of an index patient will contract the flu during an outbreak. Postexposure prophylaxis with amantadine or rimantadine is often used and has proved effective in

Publication: American Family Physician

Faster Relief from Influenza Symptoms for 'High Risk' and Otherwise Healthy P...
Clinical Trial Data Show Up to a 2.5-Day Reduction in Time to Alleviation of Symptoms of Influenza MELBOURNE, Australia, Nov. 17 /PRNewswire/ - Biota Holdings Limited has been advised by its development partner, Glaxo Wellcome (NYSE: GLX), that the results of two Phase III clinical trials of

Publication: PR Newswire

Inhaled Zanamivir Beats Rimantadine.
TORONTO - The new, inhaled anti-influenza drug, zanamivir, was more effective than rimantadine for preventing flu transmission in nursing homes in a head-to-head comparison. This finding supports the use of zanamivir for institutional outbreak control, Dr. Stefan Gravenstein said at the annual

Publication: Family Practice News

Zanamivir provides effective influenza prophylaxis in exposed family members
San Francisco-The inhaled neuraminidase inhibitor zanamivir can prevent influenza acquisition within families, reported Frederick Hayden, MD. The drug, which recently received market clearance for the treatment of influenza, works by inhibiting the neuraminidase of both influenza A and B viruses.

Publication: Formulary

Effects of Zanamivir on the Course of Influenza.
Zanamivir represents a new class of antiviral agents known as neuraminidase inhibitors. In vitro and in vivo studies have demonstrated that zanamivir exerts activity against influenza virus types A and B. Monto and colleagues evaluated the clinical efficacy and safety of zanamivir in a double-blind

Publication: American Family Physician